Healthcare provider profile · identity verified

Amal Alkhalafawi, MD

Internal Medicine · ELMWOOD PARK, IL · NPI 1770561789

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	477	118
Amlodipine Besylate	Amlodipine Besylate	284	59
Pantoprazole Sodium	Pantoprazole Sodium	262	77
Eliquis	Apixaban	193	34
Metoprolol Succinate	Metoprolol Succinate	191	48
Levothyroxine Sodium	Levothyroxine Sodium	190	39
Losartan Potassium	Losartan Potassium	170	44
Gabapentin	Gabapentin	169	41
Metformin Hcl	Metformin Hcl	130	36
Metoprolol Tartrate	Metoprolol Tartrate	130	30
Furosemide	Furosemide	129	36
Tamsulosin Hcl	Tamsulosin Hcl	104	23
Albuterol Sulfate Hfa	Albuterol Sulfate	100	24
Lisinopril	Lisinopril	96	25
Warfarin Sodium	Warfarin Sodium	88	suppressed
Alprazolam	Alprazolam	78	suppressed
Bumetanide	Bumetanide	78	23
Tramadol Hcl	Tramadol Hcl	73	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	68	suppressed
Hydralazine Hcl	Hydralazine Hcl	64	15
Potassium Chloride	Potassium Chloride	63	15
Levetiracetam	Levetiracetam	61	suppressed
Famotidine	Famotidine	57	13
Jardiance	Empagliflozin	56	14
Glipizide	Glipizide	53	12
Mirtazapine	Mirtazapine	53	suppressed
Labetalol Hcl	Labetalol Hcl	48	suppressed
Spironolactone	Spironolactone	48	11
Atenolol	Atenolol	47	13
Omeprazole	Omeprazole	46	14
Lactulose	Lactulose	45	suppressed
Amiodarone Hcl	Amiodarone Hcl	41	suppressed
Azithromycin	Azithromycin	41	25
Nifedipine Er	Nifedipine	40	suppressed
Prednisone	Prednisone	38	15
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	36	suppressed
Ventolin Hfa	Albuterol Sulfate	35	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	34	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	34	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	33	suppressed
Divalproex Sodium	Divalproex Sodium	33	suppressed
Pregabalin	Pregabalin	33	suppressed
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Memantine Hcl	Memantine Hcl	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	31	11
Trazodone Hcl	Trazodone Hcl	31	suppressed
Aripiprazole	Aripiprazole	30	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	29	suppressed
Allopurinol	Allopurinol	28	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	suppressed
Simvastatin	Simvastatin	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Donepezil Hcl	Donepezil Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Hydrocortisone	Hydrocortisone	24	suppressed
Irbesartan	Irbesartan	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Novolog Flexpen	Insulin Aspart	23	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Enulose	Lactulose	21	suppressed
Midodrine Hcl	Midodrine Hcl	21	suppressed
Phenobarbital	Phenobarbital	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Cefuroxime	Cefuroxime Axetil	20	13
Celecoxib	Celecoxib	20	suppressed
Gemfibrozil	Gemfibrozil	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Latanoprost	Latanoprost	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Calcium Acetate	Calcium Acetate	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Flecainide Acetate	Flecainide Acetate	18	suppressed
Brilinta	Ticagrelor	17	suppressed
Diazepam	Diazepam	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	16	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Nystatin	Nystatin	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	14	suppressed
Carvedilol	Carvedilol	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	suppressed
Trueplus Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	suppressed
Dilt-Xr	Diltiazem Hcl	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Finasteride	Finasteride	13	suppressed
Metolazone	Metolazone	13	suppressed
Risperidone	Risperidone	13	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Phenytoin	Phenytoin	12	suppressed
Rivastigmine	Rivastigmine Tartrate	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Cefdinir	Cefdinir	11	suppressed
Dextrose 5%-0.45% Nacl	Dextrose 5 %-0.45 % Sod Chlord	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Ramipril	Ramipril	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error